Related Experiment Video

Updated: Mar 22, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions:

Nishank Jain1, Robert F Reilly2,3

  • 1Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas.

Seminars in Dialysis
|April 11, 2016
PubMed

Insights

Clopidogrel may be less effective for hemodialysis patients with kidney disease. This review examines studies and discusses alternatives to clopidogrel for preventing ischemic events in these patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Oral P2Y12 receptor inhibitors are crucial for patients with coronary artery disease, especially those undergoing hemodialysis (HD).
  • Clopidogrel is a widely used, cost-effective P2Y12 inhibitor, but its efficacy in kidney disease patients is increasingly questioned.
  • Newer agents like prasugrel and ticagrelor exist but are more expensive.

Purpose of the Study:

  • To review evidence suggesting reduced clopidogrel effectiveness in hemodialysis patients.
  • To explore pharmacokinetic and pharmacodynamic factors contributing to potential clopidogrel inefficacy.
  • To discuss the risks and benefits of alternative antiplatelet therapies for HD patients.

Main Methods:

  • Literature review of studies investigating P2Y12 inhibitor efficacy in hemodialysis patients.
  • Analysis of pharmacokinetic and pharmacodynamic data related to clopidogrel metabolism and action in renal impairment.
  • Comparative assessment of clopidogrel versus alternative therapies in the context of kidney disease.

Main Results:

  • Accumulating evidence indicates potential reduced efficacy of clopidogrel in preventing ischemic events in patients with kidney disease.
  • Pharmacokinetic and pharmacodynamic variations may explain clopidogrel's diminished effectiveness in hemodialysis patients.
  • The review highlights the need for careful consideration of antiplatelet strategies in this vulnerable population.

Conclusions:

  • Clopidogrel's effectiveness may be compromised in patients on hemodialysis.
  • Further research into alternative P2Y12 inhibitors is warranted for hemodialysis patients with coronary artery disease.
  • Individualized antiplatelet therapy selection is crucial for optimizing outcomes in kidney disease patients.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
543
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
2.3K
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.7K